Contributing Factors Differences in genetics, hormone levels, lifestyle habits, and treatment adherence can all influence outcomes
So when taken alongside carnitine, ALA provides the body with all-round cellular support
While the nephroprotective effects of SGLT2i were initially derived from secondary endpoints of CV outcome trials (CVOTs), direct confirmation came from dedicated kidney focused trials: CREDENCE (Perkovic et al NEJM 2019| NephJC Summary), DAPA-CKD (Heerspink et al NEJM 2020| NephJC Summary) and finally EMPAKIDNEY (Herrington et al NEJM 2023| NephJC Summary)
Speak to your healthcare provider for more information
Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes
For example, cancer risk may emerge only 3-5 more years down the road or longer. Most data come from lab studies with animals rather than human trials